Clinical PracticeManagement of Pigmented Conjunctival Lesions
Introduction
Pigmented lesions on the ocular surface mainly include conjunctival melanoma (CMM), primary acquired melanosis (PAM) with and without atypia, nevus, and complexion-associated melanosis. CMM is a malignant tumor that can destroy locally the tissues of the eye and can spread systemically and result in lymph node and distant metastasis. PAM with atypia can transform into CMM, but clinically it cannot be distinguished from PAM without atypia, which has no potential for malignant transformation. Nevus has a very small risk of developing into CMM, and complexion-associated melanosis is benign.1, 2, 3
Pigmented conjunctival lesions present a management challenge because they have overlapping clinical features, but specific risks for malignancy. In this review, we present clinically salient aspects of pigmented conjunctival lesions with the goal of enabling the ophthalmic clinician to diagnose and manage them successfully. Epidemiology, current diagnostic methods, treatment options, and possible future therapies such as targeted molecular therapy and genetic evaluation are reviewed.
Section snippets
Epidemiology of Pigmented Conjunctival Lesions
In a clinical survey of 1643 consecutive conjunctival lesions at an ocular oncology referral center (Wills Eye Institute), the tumor was classified most often as melanocytic (53%), of which nevus was most common (52%), followed by melanoma (25%), and PAM (21%).1
Clinical Examination
Clinical examination should include:
- 1.
History (age, history of sun exposure, previous skin cancer, other cancer, long-term presence of the lesion versus recent change, symptoms, review of old photographs).
- 2.
Physical examination (lymph node palpation, external skin changes, eyelid and orbital signs, location of the lesion on the conjunctiva or other tissues).
- 3.
Slit lamp biomicroscopy including examination of the ocular surface, fornix, tarsal conjunctiva (with eyelids everted), anterior chamber,
Conjunctival Melanoma
CMM is composed of malignant melanocytic cells, which can be demonstrated by nuclear atypia, lack of cellular organization, or prominent nucleoli. In principle, four different cell types can be observed: small polyhedral cells, large epithelioid cells, spindle cells, and balloon cells. Features suggestive of melanoma rather than nevus are: intraepithelial involvement (especially in an older individual) with pagetoid spread; an intraepithelial component that vertically extends into the
Conjunctival Melanoma
The discussion of prognosis of CMM can be divided into prognosis for local recurrence on the eye, and systemic prognosis for metastasis and death.
CMM frequently recurs locally after surgery. Recurrence or new melanoma growth at any site on the conjunctiva in the Shields series was 45% at 5 years and 59% at 10 years. The interval to first recurrence was at a median of 14 months.6
With regard to systemic involvement, CMM carries a significant risk for metastasis and melanoma-related death. In a
Management
Management should be individually tailored for specific lesions and patients. Even the most seemingly benign lesions require careful evaluation. Although complexion-associated melanosis is not reported to undergo malignant transformation, conjunctival melanoma does occur in people with dark complexions.6 Thus, every patient requires a thorough examination to identify the lesion, evaluate the risk, and plan optimal treatments, which are described below.
Management of Recurrence
It is known that both CMM and PAM have a great tendency to recur after treatment, as was described in the prognosis section. The options for treatment of recurrence are re-excision with cryotherapy and amniotic membrane placement, cryotherapy alone, topical chemotherapy with mitomycin-C or interferon-alpha-2b, radiation or, in severe cases, enucleation. The decision for treatment is made individually; however, patients with a history of melanoma and recurrent pigment should be treated
Timing of Ophthalmic Intraocular Surgery
Intraocular invasion of ocular surface malignancies after ocular surgery is a rare event, but it has been reported.59 If there is change of a pigmented lesion or if extensive PAM is present, the pigmented lesion should be dealt with prior to intraocular surgery. Preferably, a histopathologic diagnosis should be obtained either by full excision or map biopsy. The ocular surface should be free of tumor and stable prior to intraocular surgery.
Genetics of Melanoma and Potential for New Therapies
Cancer is likely a genetic disease. Cancerogenesis is driven by mutations of oncogenes, which are genes that control hallmark features of cancer, such as cell proliferation and survival. These events can be the result of abnormal activation of a pro-proliferation or deactivation of a pro-apoptotic gene. Human cancer is probably the result of a critical accumulation of such mutations.60 Knowledge about oncogenes and their mutations is pivotal for the understanding of cancer and for the
Summary and Conclusions
CMM, PAM, nevus, and complexion-associated melanosis may have overlapping clinical features, but they differ considerably in their potential for malignancy and metastasis. Thus, accurate diagnosis is essential for designing treatment. Clinical acumen, careful observation, and biopsy all play a role for these lesions to be diagnosed and managed successfully. Histological diagnosis can be made by full excision or map biopsies. CMM must be fully excised and recurrences managed aggressively. The
References (69)
- et al.
Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors
Ophthalmology
(2004) - et al.
Conjunctival melanoma: is it increasing in the United States?
Am J Ophthalmol
(2003) - et al.
Conjunctival melanoma: is it increasing in the United States?
Am J Ophthalmol
(2003) - et al.
Conjunctival melanosis and melanoma
Ophthalmology
(1984) - et al.
Conjunctival nevi clinical features and therapeutic outcomes
Ophthalmology
(2010) Differential diagnosis of the conjunctival melanoses
Ann Diagn Pathol
(1998)- et al.
Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva
Ophthalmology
(1989) - et al.
Primary acquired melanosis of the conjunctiva
Hum Pathol
(1985) - et al.
Benign conjunctival melanocytic lesions. Clinicopathologic features
Ophthalmology
(1989) - et al.
Tumors of the conjunctiva and cornea
Surv Ophthalmol
(2004)
Pigmented squamous cell carcinoma in situ of the conjunctiva in 5 cases
Ophthalmology
Assessment of anterior segment tumors with ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases
Ophthalmology
Anterior segment optical coherence tomography of conjunctival nevus
Ophthalmology
Ultra-high resolution coherence tomography for differentiation of ocular surface squamous neoplasia and pterygia
Ophthalmology
Diagnosis and management of conjunctival and corneal intraepithelial neoplasia using ultra high-resolution optical coherence tomography
Ophthalmology
Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients
Ophthalmology
Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades
Ophthalmology
Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva
Ophthalmology
Conjunctival melanoma
Surv Ophthalmol
Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy
Am J Ophthalmol
Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma. Experience with 62 cases
Ophthalmology
Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences
Ophthalmology
Guidelines of care for the management of primary cutaneous melanoma
J Am Acad Dermatol
Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia
Ophthalmology
The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C
Am J Ophthalmol
Time trends in the incidence of conjunctival melanoma in Sweden
Br J Ophthalmol
Latitude and incidence of ocular melanoma
Photochem Photobiol
Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases
Ophthalmology
Primary acquired melanosis of the conjunctiva: experience with 311 eyes
Trans Am Ophthalmol Soc
Conjunctival nevi: clinical features and natural course in 410 consecutive patients
Arch Ophthalmol
Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases
Br J Ophthalmol
Diagnosis and management of pigmented lesions of the conjunctiva
Techniques in Ophthalmology
Multifocal amelanotic conjunctival melanoma and acquired melanosis sine pigmento
Br J Ophthalmol
Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva
Graefes Arch Clin Exp Ophthalmol
Cited by (43)
Melanocytic lesions of the conjunctiva: an up-to-date review
2024, Diagnostic HistopathologyClinic-pathological agreement in the diagnosis of conjunctival tumours: Analysis of 195 cases
2023, Archivos de la Sociedad Espanola de OftalmologiaDiagnosis and Management of Ocular Surface Neoplasia
2023, Advances in Ophthalmology and OptometryAdopting low-shot deep learning for the detection of conjunctival melanoma using ocular surface images
2021, Computer Methods and Programs in BiomedicineCitation Excerpt :Conjunctival nevus is a very common condition with a broad spectrum of clinical manifestations. Its routine clinical practice involves frequent encounters with patients who inquire about their conjunctival pigmented lesions [1]. This could have a variety of benign or malignant features [2].
Ocular Oncology—Primary and Metastatic Malignancies
2021, Medical Clinics of North AmericaConjunctival melanoma in an African American man
2020, American Journal of Ophthalmology Case ReportsCitation Excerpt :Conjunctival melanoma was suspected and the patient underwent excisional biopsy with amniotic membrane graft. During the removal of the tumor, wide local excision using the “no touch” technique was used followed by freeze-thaw cryotherapy.1 The amniotic membrane graft was used to cover the entire bulbar conjunctival surface and was fixed into position with fibrin sealant glue.
Supported in part by NIH Center Core Grant P30EY014801, Research to Prevent Blindness Unrestricted Grant, Department of Defense (DOD- Grant#W81XWH-09-1-0675), The Ronald and Alicia Lepke Grant, The Jimmy and Gay Bryan Grant, The Hager Family Grant and the Max-Kade-Foundation, NY.
The authors have no financial interest in any concept or products described in this article.
Single-copy reprint requests to Carol L. Karp, MD (address below).